IGFBP2
Overview
IGFBP2 (Insulin-like Growth Factor Binding Protein 2) is a secreted modulator of the IGF signaling axis. It binds IGF-I and IGF-II to regulate their bioavailability. IGFBP2 has been reported both as a potential oncogene (overexpressed in glioma, breast, and prostate cancers) and as a modifier of PI3K/AKT pathway activity. In the adenoid cystic carcinoma (ACC) exome study, IGFBP2 carries a somatic mutation, linking it to the IGF-axis alterations observed in this tumor type.
Alterations observed in the corpus
- Mutation observed in adenoid cystic carcinoma (ACC); identified as an IGF-axis modulator in the context of a broader PI3K/receptor tyrosine kinase signaling landscape in ACC PMID:23685749
- IGFBP2 elevated in BRAF hot-spot mutant melanomas by reverse-phase protein array (RPPA) in the TCGA 333-sample cutaneous melanoma cohort PMID:26091043
Cancer types (linked)
- ACC (adenoid cystic carcinoma): somatic mutation detected in whole-exome sequencing study; functional significance in ACC not characterized.
Co-occurrence and mutual exclusivity
- Mutation co-occurs in an ACC genomic landscape dominated by MYB-NFIB fusions and chromatin-remodeling gene mutations; its relationship to these drivers is not established PMID:23685749
Therapeutic relevance
- Not directly targeted in the corpus; IGF-axis inhibitors are a general therapeutic consideration in tumors with IGF pathway alterations.
Open questions
- Functional consequence of the IGFBP2 mutation in ACC, and whether it modulates the PI3K/AKT pathway in this context, has not been tested PMID:23685749
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:26091043
This page was processed by crosslinker on 2026-05-14.